Compliant AI Video Ads for Supplement Brands UK: Cross-Regulator Framework

UK supplement advertising sits under three distinct regulatory bodies that operate to different procedural standards. The ASA enforces the CAP code through complaints and rulings. The MHRA defines the line between food supplement and unlicensed medicinal product, and prosecutes when products cross it. The Food Standards Agency oversees nutrition labelling. AI video tools operate inside none of these frameworks by default. The brief is what holds them inside.

DTC supplement brands shipping at scale in the UK have converged on a small set of practices: brief discipline anchored to the EU authorised health claims register, post-generation review against the prohibited-claim allowlist, and occasional Copy Advice consultation for borderline phrasings. These are operational habits, not creative ones. The brands that treat compliance as a creative constraint produce better-performing ads than the brands that treat it as an obstacle.

What follows is the cross-category framework UK supplement brands use for AI video, with the per-category specifics covered in companion articles.

The three regulators and what each enforces

The ASA enforces the UK Code of Non-broadcast Advertising and Direct & Promotional Marketing (CAP code). Section 15 covers food, food supplements, and associated health or nutrition claims. The ASA operates procedurally rather than punitively: it receives complaints, investigates, and issues rulings. Brands can be required to remove or modify ads, and repeated rulings draw escalating attention. Ad accounts can be terminated by Meta following ASA rulings, which is the operational consequence brands feel most directly.

The MHRA enforces the line between food supplement and medicine. A product whose marketing implies the prevention, treatment, or cure of disease is treated as a medicinal product regardless of formulation. Selling an unlicensed medicinal is a criminal offence. The MHRA enforces this through investigation and prosecution, including in cases where the product itself is sold legally as a supplement but the advertising crosses the line into medicinal claims.

The FSA oversees nutritional labelling under retained EU regulation, including the threshold rules that determine when an authorised health claim can be made. The FSA's role in advertising is largely indirect; the substantive ad-claim enforcement sits with the ASA, working from the same authorised-claims register the FSA implements on labelling.

For platform-aware tooling that handles these dimensions specifically, see AI video tools that handle ASA compliance UK.

The CAP code section 15 framework

CAP code section 15 sets out the rules for food supplement advertising. The structural points relevant to AI video generation:

• Health claims have to come from the authorised register or be acceptable equivalents of authorised wording.
• Nutrition claims have to come from the authorised register and meet the threshold rules.
• Ads must not state or imply that a balanced and varied diet cannot provide appropriate quantities of nutrients.
• Ads must not encourage excessive consumption.
• Ads must not state or imply that the product is necessary for the maintenance of health.

The first two points are the most-cited in rulings. AI video tools default to claim wording that goes beyond authorised equivalents, particularly with outcome-language ("fixes", "cures", "boosts"). The brief discipline has to encode the authorised-equivalent register explicitly.

The authorised-claims register principle

The UK has retained the EU register of authorised nutrition and health claims, established under Regulation 1924/2006 and implemented through Regulation 432/2012 and subsequent amendments. The register lists specific claims for specific nutrients at specific thresholds. A claim that does not appear on the register, or that is not an acceptable equivalent of one that does, is non-compliant.

The register is searchable. Brands operating at scale typically build a claim-allowlist for their formulations: per ingredient, per threshold, the authorised wording and acceptable variations. The allowlist becomes the brief constraint that AI tools generate against.

Examples by category:

• Vitamins: extensive register, covered in AI video ads for vitamin brands.
• Magnesium: seven authorised claims, covered in AI testimonial scripts for magnesium supplements.
• Protein: five authorised claims, covered in AI video ads for protein powder brands.
• Caffeine and creatine: dose-dependent authorised claims.
• Collagen: empty register, cofactor pivot required, covered in AI video ads for collagen supplements.
• Probiotics: empty register, cofactor pivot required.

The pattern across all supplement sub-categories is consistent. The brief encodes the authorised wording. The model generates against it. The review verifies it.

AI video specifically: the brief discipline

The AI video brief for compliant UK supplement ads has six elements:

• The talent profile (age, presence, register).
• The visual setting (interior, lighting, time of day).
• The product context (form, dose, format).
• The claim wording (authorised wording verbatim, with the cofactor reference).
• The negative-constraint instructions (prohibited words, prohibited framings).
• The audience caveat where relevant (training context, geography, age range).

AI video tools default to omitting elements four and five entirely. The brief has to make them explicit. The pattern transfers across sub-categories: protein, magnesium, vitamin, nootropic, collagen, probiotic, sleep. The specifics differ; the structure is identical.

Cost economics for compliant AI generation

A traditional UGC creator with wellness-category positioning charges £400 to £1,200 per finished supplement ad. The 12 to 25 variants per month required for sustained Meta performance puts creator-only spend between £4,000 and £30,000 monthly before media costs.

AI generation through a vertical-aware platform produces the same volume for £50 to £400 monthly, depending on model selection and per-variant runtime. The cost differential is two orders of magnitude. The expensive part of the pipeline is no longer production; it is the brief library, the compliance review, and the testing infrastructure.

The cost shift does not reduce the regulatory burden. Brand teams that treat AI as a budget unlock without recognising the brief discipline required for UK compliance produce more variants, but more of them get reported. The teams that build the brief library first, then scale variants, produce sustainable performance.

The hybrid creator-AI pattern

UK supplement brands operating at scale typically run a hybrid creator-AI pattern. AI generates 80% to 90% of variant volume, anchored to the authorised-claims register through the brief library. Human creators produce two or three hero placements per quarter, where authentic association justifies the rate.

The hybrid pattern outperforms either approach in isolation. AI alone produces variant volume but lacks the authentic emotional register that hero placements depend on. Creator alone produces hero quality but cannot scale to the variant volume Meta now requires for sustained performance. The combination is what produces lower CPA than either model in isolation.

The cross-vertical UGC framework is documented in AI generated UGC for supplement brands, where the cost and authenticity dimensions are treated in detail.

FAQ

Does the UK still follow EU supplement law after Brexit?

Yes, in substance. The EU register of authorised health claims has been retained in UK law. Subsequent EU amendments are reviewed by UK regulators and adopted on a case-by-case basis. The practical effect is that UK supplement compliance and EU supplement compliance remain closely aligned, with UK-specific divergence appearing slowly.

How does the MHRA decide a product is a medicinal claim?

The MHRA assesses claims in context, including the wording, the visual presentation, and the consumer impression created. A claim that the product treats, prevents, or cures a recognised medical condition is the most reliable trigger. Implied claims through visual cues (medical-clinical imagery, white-coat presentation) can also push borderline products into the medicinal classification.

Is Copy Advice useful for AI-generated supplement ads?

Yes, particularly for borderline categories like nootropics, collagen, and probiotics where the authorised-claims register is narrow or empty. The ASA's Copy Advice service reviews proposed ad copy before publication and is free to use. Brands shipping high variant volumes do not run every variant through Copy Advice, but they do submit category-defining scripts to establish the safe register.

How does AI disclosure affect the compliance position?

The CAP code requires testimonials to be genuine and not misleading. A synthetic creator presented as a real customer triggers a misleading-practice complaint. Disclosure of AI generation, in copy or as a corner watermark, is the safer position. The disclosure expectation is moving toward mandatory across all UK consumer advertising.

Does the UK accept US clinical evidence for substantiation?

For ASA purposes, evidence quality matters more than jurisdiction. US clinical trials can substantiate UK claims if the evidence base is sound and applies to the formulation being advertised. The structural distinction is between substantiation evidence (which is jurisdiction-neutral) and authorised claim wording (which is jurisdiction-specific). The wording has to match the UK register; the evidence supporting the claim does not.

For the cross-jurisdictional FTC equivalent, see FTC compliance for supplement ads in 2026.

---

100 free credits to test how Tonic handles UK supplement-category briefs across the authorised-claims register: tonicstudio.ai/signup?promo=UGC100.